Comparison of clinical outcomes of Schirmer's test with dry eye
Jeffrey Gemi, MD, Ora Inc., speaks on the highlights from his presentation comparing Schirmer's test with other clinical outcomes in dry eye.
Common Causes of Dry Eye Disease
The impact of autoimmune and systemic diseases as well as environmental triggers on the development of dry eye disease.
Identifying Dry Eye Disease
A panel of ophthalmologists and optometrists begin a discussion on the management of dry eye disease by defining the condition and highlighting common symptoms.
Company launches product targeting dry eye, MGD
ThermaMEDx has unveiled a self-heating, pre-moistened, disposable, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction.
Bausch + Lomb announces topline results for phase III trial of NOV03 to treat DED associated with MGD
Bausch + Lomb and Novaliq GmbH have announced statistically significant topline data from the first phase 3 trial analyzing the investigational drug NOV03 as a first-in-class eye drop to treat dry eye disease associated with MGD.
Treatment option for dry eye secondary to graft-vs-host disease
Product offers improvement in objective dry eye disease measures, providing relief.
Minocycline shows promise in dry eye trial
Phase 2 trial of 0.3% minocycline microparticle suspension shows promise in dry eye diseases associated with Inflamed meibomian gland dysfunction
Mask up ... and dry out?
Cynthia Matossian, MD, FACS, ABES, explores the tie between mask wear and dry eye, causes behind a growing number of MGD cases, and offers mask safety tips for patient treatment.
Results of dry eye trial released
RegeneRx Biopharmaceuticals announces that its ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops did not meet its primary outcome measures.
Managing pandemic-driven dry eye with nutrition
Peter J. Polack, MD, FACS, of Ocala Eye, discusses how proper patient education and nutrition have been key to managing an increase in dry eye patients during the pandemic.
Oyster Point Pharma receives FDA filing acceptance of NDA for OC-01 nasal spray to treat DED
The FDA has accepted Oyster Point Pharma's New Drug Application (NDA) for its OC-01 (varenicline) nasal spray to treat dry eye disease.
Investigators zoom in on future of dry eye treatment
Autologous serum eye drops and blood products offer hope to patients.
The sky is the limit for allergy pipeline
Growing patient pool is driving clinical trial investment.
Study: Sore eyes a common symptom in COVID-19 patients
Ocular symptoms in COVID-19 patients may be more common than previously thought — with sore eyes a significant sign of disease.
Glaucoma and dry eye present double trouble for patients, ophthalmologists
Sunita Radhakrishnan, MD, in a presentation at the 25th annual Glaucoma Symposium at the Glaucoma 360 virtual annual event, noted that concomitant treatment of both glaucoma and dry eye is key.
The MGD patient journey: maintenance over time
Cynthia Matossian, MD, FACS, ABES, continues her discussion on MGD treatment by explaining why it's important for patients to understand that MGD and dry eye are lifelong, chronic conditions requiring regular maintenance and monitoring.
Treating Demodex blepharitis efficiently before surgery
New options open possibilities for treatment, resulting in better outcomes for patients.
Zeroing in on dry eye treatment for patients with cataracts
Study supports preoperative ocular surface optimization with artificial tears.
Short-term dry eye treatment option receives FDA approval
A novel ocular corticosteroid is offering hope of quick results for patients.
Dr. Mali's top 5 predictions for ophthalmology in 2021
In light of an unprecedented year filled with technological advancements and pivots, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2021.
Safety, efficacy of KPI-121 0.25% for DED treatment
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.
Novel agents in the pipeline for dry eye disease
Agents in the pipeline for dry eye disease
Overlapping diseases and the impact of COVID-19
Counseling and formulary concerns for dry eye therapies
Challenges in the management of dry eye
Treatment methods for aqueous dry eye
In-office procedures and patient resistance for dry eye treatments
Treating meibomian gland dysfunction
The role of nutritional supplements and antibiotics in dry eye
2 Clarke Drive Cranbury, NJ 08512